ClinicalTrials.gg
CompletedNCT02875834HARMONIZE GLUpdated Aug 19, 2020Results posted

A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia

A Phase 3 interventional study of Sodium Zirconium Cyclosilicate (ZS) 10g and Sodium Zirconium Cyclosilicate (ZS) 5g in Hyperkalemia, sponsored by AstraZeneca. Completed at 45 sites in 4 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2020-08-19.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
267
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia — 3 open to participants now, 4 under way, none of them phase 3. sodium zirconium cyclosilicate · Hyperkalemia.

Enrollment
6th of 27
267 · median 120
Started
2017
with 3 others
Phase 3
12 of 27
none open now
Registered
4th of 27
by date
Lead sponsor
16 of 27
AstraZeneca

Among the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, this one is the 6th largest by enrollment, is one of 4 that started in 2017, is one of 12 in phase 3, and was the 4th registered.

Hyperkalemia

134 studies on the registry are indexed under Hyperkalemia; 26 are open to participants now.

Browse Hyperkalemia studies →

Open to participants now

3 of the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sodium zirconium cyclosilicate

sodium zirconium cyclosilicate: first FDA approval 2018 (LOKELMA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Hyperkalemia studies recruiting now, 11 (69%) set no upper age limit and 2 (13%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, or all of them as a file.
02

Study summary

To evaluate the efficacy of two different doses (5 and 10 g) of ZS orally administered once daily (qd) vs placebo in maintaining normokalemia in initially hyperkalemic patients having achieved normokalemia following two days of initial ZS therapy (10g TID).

03

Conditions studied

  • Hyperkalemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of prior to any study specific procedures
  • Female and male patients aged ≥18 and ≤ 90 years
  • Two consecutive i-STAT potassium values, measured 60-minutes (± 10 minutes) apart, both ≥ 5.1 mmol/l and measured within 1 day of the first ZS dose on 48-hour open-label initial phase Day 1
  • Ability to have repeated blood draws or effective venous catheterization
  • Female patients must be 1 year , surgically sterile, or using an acceptable method of for the duration of the study and for 3 months after the last dose of ZS/matching placebo to prevent pregnancy.

Exclusion criteria

Exclusion Criteria:

  • Involvement in the planning and/or conduct of the study
  • Participation in another clinical study with an product during the last 3 months
  • Pseudohyperkalemia signs and symptoms
  • Patients treated with lactulose, xifaxan (rifaximin) or other non-absorbed antibiotics for hyperammonemia within 7 days prior to the first dose of study drug
  • Patients treated with resins,calcium acetate,calcium carbonate, or lanthanum carbonate,within 7 days prior to the first dose of study drug
  • Patients with a of less than 3 months
  • Patients who are severely physically or mentally incapacitated and who in the opinion of investigator are unable to perform the subjects' tasks associated with the protocol
  • Female patients who are pregnant, lactating, or planning to become pregnant
  • Patients with diabetic ketoacidosis
  • Presence of any condition which, in the opinion of the investigator, places the patient at undue risk or potentially jeopardizes the quality of the data to be generated
  • Known or previous anaphylaxis to ZS or to components thereof
  • Patients with cardiac arrhythmias that require immediate treatment
  • Patients on dialysis
  • Patients who are blood donors should not donate blood during the study and for 3 months following their last dose of ZS
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
267 participants (actual)

Study arms

  • Experimental
    Sodium Zirconium Cyclosilicate (ZS) 5g

    Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.

    Drug: Sodium Zirconium Cyclosilicate (ZS) 5g

  • Experimental
    Sodium Zirconium Cyclosilicate (ZS) 10g

    Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.

    Drug: Sodium Zirconium Cyclosilicate (ZS) 10g

  • Placebo comparator
    Placebo

    Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.

    Drug: Placebo

Interventions

  • Suspension administered 10g orally three times per day, in the first 48-hour of the study for all patients (48-hour open label initial phase)

  • Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.

  • Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.

  • DrugPlacebo

    Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.

06

What researchers measure

Primary outcomes

  1. Least Square Mean S-K Level on Days 8-29

    Comparison between placebo and the active ZS treatment groups (each dose group will be sequentially compared with placebo, starting with the highest and ending with the lowest dose) with regard to the mean S-K level during the 28-day randomized treatment study phase Days 8-29. The results in the table below are presented for RTP.

    Time frame: Through 28-day randomized treatment study phase day 8-29.

Secondary outcomes

  1. Proportion of Patients Achieving Normokalemia

    Proportion of patients who achieve normokalemia during the initial phase at 24 and 48 hours. The results in the table below are presented for OLP. (h=hours).

    Time frame: Through 48-hour initial phase.

  2. Exponential Rate of Change in S-K Levels

    Exponential rate of change in S-K levels (blood) during the 48-hour open-label initial phase. The results in the table below are presented for OLP.

    Time frame: Through 48-hour initial phase.

  3. Absolute Change From Baseline in S-K Levels

    Absolute change from baseline in S-K levels at all measured time intervals. The results in the table below are presented for OLP.

    Time frame: Through 48-hour initial phase.

  4. Percentage Change From Baseline in S-K Levels

    Percentage change from baseline in S-K levels at all measured time intervals. The results in the table below are presented for OLP.

    Time frame: Through 48-hour initial phase.

  5. Proportion of Patients Remaining Normokalemic

    The proportion of patients who remain normokalemic (as defined by S-K between 3.5-5.0 mmol/l, inclusive) at the end of the 28-day randomized treatment study phase and during the 28-day randomized treatment study phase. The results in the table below are presented for RTP.

    Time frame: Through 28-day randomized treatment study phase day 8-29.

  6. Proportion of Normokalemic Patients at Day 1 Through Day 29/Exit

    The proportion of patients who are normokalemic (as defined by S-K between 3.5-5.0 mmol/l, inclusive) at Day 1 through Day 29/Exit in randomization phase. The results in the table below are presented for RTP.

    Time frame: Through 28-day randomized treatment phase.

  7. Days Patients Remain Normokalemic

    The number of days patients remain normokalemic during the 28-day randomized treatment study phase. The results in the table below are presented for RTP.

    Time frame: Through 28-day randomized treatment phase.

  8. Mean Change in S-K Levels

    The mean change in S-K levels evaluated relative to both baselines. The results in the table below are presented for RTP.

    Time frame: Through 28-day randomized treatment phase.

  9. Mean Percentage Change in S-K Levels

    The mean percentage change in S-K levels evaluated relative to both baselines. The results in the table below are presented for RTP.

    Time frame: Through 28-day randomized treatment phase.

  10. Number of Hyperkalemic Patients

    The results represent number of hyperkalemic patients during the 28-day randomized treatment study phase. The results in the table below are presented for RTP.

    Time frame: Through 28-day randomized treatment phase.

  11. Mean Changes in S-Aldosterone and P Renin Levels

    The mean changes from OLP baseline in S-Aldosterone and P-Renin levels. The results in the table below are presented for RTP.

    Time frame: Through 28-day randomized treatment phase.

  12. Patient Reported Health State (EQ-5D) Questionnaire

    Evaluate health state of patients using EQ-5D questionnaire. This scale is numbered from 0 to 100. 0 means the worst health you can imagine. 100 means the best health you can imagine. The results in the table below are presented for RTP.

    Time frame: Through study completion, an average of 37 days.

07

Results

Posted Aug 19, 2020

Participant flow

This study was conducted in 42 centers within Japan, Russia, South Korea, and Taiwan.

Open-label Phase
Participant flow — Open-label Phase
MilestoneSodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlacebo
Started267000
Completed260000
Not completed7000
Withdrew: Withdrawal by subject3000
Withdrew: (not collected)4000
Randomized Treatment Phase
Participant flow — Randomized Treatment Phase
MilestoneSodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlacebo
Started0999950
Completed0858841
Not completed014119
Withdrew: Withdrawal by subject0310
Withdrew: Protocol violation0200
Withdrew: (not collected)09109

Outcome measures

PrimaryLeast Square Mean S-K Level on Days 8-29

Comparison between placebo and the active ZS treatment groups (each dose group will be sequentially compared with placebo, starting with the highest and ending with the lowest dose) with regard to the mean S-K level during the 28-day randomized treatment study phase Days 8-29. The results in the table below are presented for RTP.

Time frame:
Through 28-day randomized treatment study phase day 8-29.
Reported as:
Least squares mean · mmol/L
Least Square Mean S-K Level on Days 8-29
mmol/LSodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlacebo
Least Square Mean S-K Level on Days 8-29—4.811 (4.685 to 4.940)4.381 (4.265 to 4.501)5.321 (5.155 to 5.493)
Statistical analysis
  • Sodium Zirconium Cyclosilicate (ZS) 5g vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.904 · 95% CI 0.876 to 0.933
  • Sodium Zirconium Cyclosilicate (ZS) 10g vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.823 · 95% CI 0.797 to 0.850
SecondaryProportion of Patients Achieving Normokalemia

Proportion of patients who achieve normokalemia during the initial phase at 24 and 48 hours. The results in the table below are presented for OLP. (h=hours).

Time frame:
Through 48-hour initial phase.
Reported as:
Number · Participants
Proportion of Patients Achieving Normokalemia
ParticipantsSodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlacebo
Normokalemic at 24h169———
Not Normokalemic at 24h93———
Missing at 24h5———
Normokalemic at 48h238———
Not Normokalemic at 48h22———
Missing at 48h7———
SecondaryExponential Rate of Change in S-K Levels

Exponential rate of change in S-K levels (blood) during the 48-hour open-label initial phase. The results in the table below are presented for OLP.

Time frame:
Through 48-hour initial phase.
Reported as:
Mean · log(mmol/L)/h
Exponential Rate of Change in S-K Levels
log(mmol/L)/hSodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlacebo
Exponential Rate of Change in S-K Levels-0.004 ± 0.0001———
SecondaryAbsolute Change From Baseline in S-K Levels

Absolute change from baseline in S-K levels at all measured time intervals. The results in the table below are presented for OLP.

Time frame:
Through 48-hour initial phase.
Reported as:
Mean · mmol/L
Absolute Change From Baseline in S-K Levels
mmol/LSodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlacebo
OLP Day 1-1h post-first dose absolute change-0.19 ± 0.444———
OLP Day 1-2h post-first dose absolute change-0.48 ± 0.452———
OLP Day 1-4h post-first dose absolute change-0.57 ± 0.494———
OLP Day 2-24h absolute change-0.81 ± 0.398———
OLP Day 2-1h post-first dose absolute change-0.91 ± 0.445———
OLP Day 3-48h absolute change-1.28 ± 0.499———
SecondaryPercentage Change From Baseline in S-K Levels

Percentage change from baseline in S-K levels at all measured time intervals. The results in the table below are presented for OLP.

Time frame:
Through 48-hour initial phase.
Reported as:
Mean · Percentage change
Percentage Change From Baseline in S-K Levels
Percentage changeSodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlacebo
OLP Day 1-1h post-first dose percentage change-3.26 ± 7.949———
OLP Day 1-2h post-first dose percentage change-8.29 ± 7.792———
OLP Day 1-4h post-first dose percentage change-9.88 ± 8.494———
OLP Day 2-24h percentage change-14.08 ± 6.479———
OLP Day 2-1h post-first dose percentage change-15.84 ± 7.243———
OLP Day 3-48h percentage change-22.16 ± 7.812———
SecondaryProportion of Patients Remaining Normokalemic

The proportion of patients who remain normokalemic (as defined by S-K between 3.5-5.0 mmol/l, inclusive) at the end of the 28-day randomized treatment study phase and during the 28-day randomized treatment study phase. The results in the table below are presented for RTP.

Time frame:
Through 28-day randomized treatment study phase day 8-29.
Reported as:
Number · Participants
Proportion of Patients Remaining Normokalemic
ParticipantsSodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlacebo
Proportion of Patients Remaining Normokalemic—587512
Statistical analysis
  • Sodium Zirconium Cyclosilicate (ZS) 5g vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 6.3436 · 95% CI 2.6866 to 14.9782
  • Sodium Zirconium Cyclosilicate (ZS) 10g vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 18.1876 · 95% CI 7.1591 to 46.2054
SecondaryProportion of Normokalemic Patients at Day 1 Through Day 29/Exit

The proportion of patients who are normokalemic (as defined by S-K between 3.5-5.0 mmol/l, inclusive) at Day 1 through Day 29/Exit in randomization phase. The results in the table below are presented for RTP.

Time frame:
Through 28-day randomized treatment phase.
Reported as:
Number · Participants
Proportion of Normokalemic Patients at Day 1 Through Day 29/Exit
ParticipantsSodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlacebo
Day 1—939445
Day 2—899340
Day 5—718927
Day 8—628116
Day 12—627812
Day 15—577712
Day 19—557611
Day 22—547311
Day 26—56748
Day 29—517111
Day 29/Exit—587712
SecondaryDays Patients Remain Normokalemic

The number of days patients remain normokalemic during the 28-day randomized treatment study phase. The results in the table below are presented for RTP.

Time frame:
Through 28-day randomized treatment phase.
Reported as:
Least squares mean · Day
Days Patients Remain Normokalemic
DaySodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlacebo
Days Patients Remain Normokalemic—10.810 ± 1.11315.623 ± 1.1433.543 ± 1.351
Statistical analysis
  • Sodium Zirconium Cyclosilicate (ZS) 5g vs Placebo · Regression, Linear · p = <0.001 · Mean difference (final values): 7.266 · 95% CI 4.318 to 10.214
  • Sodium Zirconium Cyclosilicate (ZS) 10g vs Placebo · Regression, Linear · p = <0.001 · Mean difference (final values): 12.079 · 95% CI 9.118 to 15.040
SecondaryMean Change in S-K Levels

The mean change in S-K levels evaluated relative to both baselines. The results in the table below are presented for RTP.

Time frame:
Through 28-day randomized treatment phase.
Reported as:
Mean · mmol/L
Mean Change in S-K Levels
mmol/LSodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlacebo
Day 2 change from RTP baseline—0.03 ± 0.354-0.09 ± 0.3720.17 ± 0.443
Day 5 change from RTP baseline—0.23 ± 0.478-0.08 ± 0.4390.60 ± 0.562
Day 8 change from RTP baseline—0.44 ± 0.4870.00 ± 0.4890.91 ± 0.622
Day 12 change from RTP baseline—0.53 ± 0.5600.05 ± 0.5730.97 ± 0.646
Day 15 change from RTP baseline—0.54 ± 0.5840.04 ± 0.5640.85 ± 0.585
Day 19 change from RTP baseline—0.56 ± 0.5780.05 ± 0.5760.97 ± 0.566
Day 22 change from RTP baseline—0.47 ± 0.5550.10 ± 0.6130.93 ± 0.702
Day 26 change from RTP baseline—0.51 ± 0.5810.05 ± 0.6391.01 ± 0.607
Day 29 change from RTP baseline—0.47 ± 0.5860.02 ± 0.6651.02 ± 0.594
EOS change from RTP baseline—0.92 ± 0.6610.77 ± 0.6950.88 ± 0.684
Day 2 change from OLP baseline—-1.28 ± 0.544-1.36 ± 0.515-1.07 ± 0.602
Day 5 change from OLP baseline—-1.08 ± 0.552-1.35 ± 0.601-0.64 ± 0.594
Day 8 change from OLP baseline—-0.87 ± 0.578-1.28 ± 0.634-0.34 ± 0.661
Day 12 change from OLP baseline—-0.79 ± 0.603-1.21 ± 0.671-0.28 ± 0.602
Day 15 change from OLP baseline—-0.77 ± 0.604-1.23 ± 0.643-0.40 ± 0.550
Day 19 change from OLP baseline—-0.74 ± 0.639-1.20 ± 0.672-0.30 ± 0.533
Day 22 change from OLP baseline—-0.84 ± 0.597-1.15 ± 0.730-0.38 ± 0.571
Day 26 change from OLP baseline—-0.79 ± 0.687-1.21 ± 0.762-0.28 ± 0.563
Day 29 change from OLP baseline—-0.82 ± 0.604-1.24 ± 0.734-0.27 ± 0.515
EOS change from OLP baseline—-0.39 ± 0.649-0.50 ± 0.725-0.36 ± 0.702
SecondaryMean Percentage Change in S-K Levels

The mean percentage change in S-K levels evaluated relative to both baselines. The results in the table below are presented for RTP.

Time frame:
Through 28-day randomized treatment phase.
Reported as:
Mean · Percentage change
Mean Percentage Change in S-K Levels
Percentage changeSodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlacebo
Day 2 percentage change from RTP baseline—1.00 ± 8.459-1.74 ± 7.9814.19 ± 10.592
Day 5 percentage change from RTP baseline—5.51 ± 11.337-1.52 ± 9.69114.19 ± 13.162
Day 8 percentage change from RTP baseline—10.26 ± 11.3400.16 ± 11.06221.55 ± 15.634
Day 12 percentage change from RTP baseline—12.41 ± 13.1131.60 ± 13.20522.87 ± 16.457
Day 15 percentage change from RTP baseline—12.50 ± 13.3781.27 ± 12.93720.15 ± 14.647
Day 19 percentage change from RTP baseline—13.12 ± 13.1801.70 ± 13.13922.77 ± 14.583
Day 22 percentage change from RTP baseline—11.04 ± 12.9932.66 ± 14.04222.28 ± 18.131
Day 26 percentage change from RTP baseline—12.02 ± 13.6161.49 ± 14.44123.63 ± 15.353
Day 29 percentage change from RTP baseline—11.34 ± 13.8210.87 ± 15.08423.99 ± 15.329
EOS percentage change from RTP baseline—21.62 ± 16.02717.76 ± 16.26620.70 ± 17.035
Day 2 percentage change from OLP baseline—-22.12 ± 8.679-23.55 ± 7.652-18.51 ± 9.751
Day 5 percentage change from OLP baseline—-18.77 ± 9.347-23.31 ± 9.230-10.96 ± 9.724
Day 8 percentage change from OLP baseline—-15.01 ± 9.627-22.01 ± 10.037-5.41 ± 11.424
Day 12 percentage change from OLP baseline—-13.55 ± 9.891-20.84 ± 10.981-4.57 ± 10.335
Day 15 percentage change from OLP baseline—-13.35 ± 10.170-21.18 ± 10.351-6.63 ± 9.457
Day 19 percentage change from OLP baseline—-12.79 ± 11.339-20.67 ± 10.834-4.89 ± 9.279
Day 22 percentage change from OLP baseline—-14.49 ± 10.158-19.67 ± 11.723-6.43 ± 9.759
Day 26 percentage change from OLP baseline—-13.35 ± 11.599-20.75 ± 12.360-4.74 ± 9.551
Day 29 percentage change from OLP baseline—-14.09 ± 9.949-21.42 ± 11.659-4.61 ± 8.802
EOS percentage change from OLP baseline—-6.57 ± 11.199-8.54 ± 12.405-5.95 ± 11.927
SecondaryNumber of Hyperkalemic Patients

The results represent number of hyperkalemic patients during the 28-day randomized treatment study phase. The results in the table below are presented for RTP.

Time frame:
Through 28-day randomized treatment phase.
Reported as:
Count of participants · Participants
Number of Hyperkalemic Patients
ParticipantsSodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlacebo
Number of Hyperkalemic Patients—664547
Statistical analysis
  • Sodium Zirconium Cyclosilicate (ZS) 5g vs Placebo · Regression, Cox · p = <0.001 · Hazard ratio (hr): 0.443 · 95% CI 0.2954 to 0.6631
  • Sodium Zirconium Cyclosilicate (ZS) 10g vs Placebo · Regression, Cox · p = <0.001 · Hazard ratio (hr): 0.158 · 95% CI 0.0992 to 0.2508
SecondaryMean Changes in S-Aldosterone and P Renin Levels

The mean changes from OLP baseline in S-Aldosterone and P-Renin levels. The results in the table below are presented for RTP.

Time frame:
Through 28-day randomized treatment phase.
Reported as:
Mean · pmol/L
Mean Changes in S-Aldosterone and P Renin Levels
pmol/LSodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlacebo
Day 1 S-Aldosterone—-112.69 ± 178.358-85.63 ± 118.017-98.54 ± 168.657
Day 15 S-Aldosterone—-91.75 ± 179.791-96.37 ± 108.00239.78 ± 152.050
Day 29 S-Aldosterone—-102.70 ± 212.187-90.22 ± 91.14941.07 ± 198.266
Day 1 P-Renin—-0.23 ± 1.158-0.26 ± 1.913-0.30 ± 1.031
Day 15 P-Renin—-0.39 ± 1.350-1.09 ± 4.7320.60 ± 3.250
Day 29 P-Renin—-0.27 ± 1.008-1.56 ± 4.165-0.25 ± 2.725
SecondaryPatient Reported Health State (EQ-5D) Questionnaire

Evaluate health state of patients using EQ-5D questionnaire. This scale is numbered from 0 to 100. 0 means the worst health you can imagine. 100 means the best health you can imagine. The results in the table below are presented for RTP.

Time frame:
Through study completion, an average of 37 days.
Reported as:
Mean · Units on a scale
Patient Reported Health State (EQ-5D) Questionnaire
Units on a scaleSodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlacebo
OLP baseline—75.0 ± 16.4474.3 ± 17.4472.7 ± 17.32
Day 29—77.6 ± 16.5076.9 ± 16.0876.6 ± 14.08

Adverse events

Collected over Through 28-day randomized treatment study phase day 8-29. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sodium Zirconium Cyclosilicate (ZS) 10g Tid0/267 (0%)0/267 (0%)0/267 (0%)
Sodium Zirconium Cyclosilicate (ZS) 5g0/99 (0%)4/99 (4%)6/99 (6.1%)
Sodium Zirconium Cyclosilicate (ZS) 10g0/99 (0%)3/99 (3%)21/99 (21.2%)
Placebo0/50 (0%)1/50 (2%)0/50 (0%)
Most frequent serious events
Most frequent serious events
EventSodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlacebo
Ankle fractureInjury, poisoning and procedural complications0/2670/990/991/50
CystitisInfections and infestations0/2670/991/990/50
Infectious colitisInfections and infestations0/2671/990/990/50
PneumoniaInfections and infestations0/2671/990/990/50
Upper respiratory tract infectionInfections and infestations0/2670/991/990/50
Cardiac failureCardiac disorders0/2670/991/990/50
Cardiac failure congestiveCardiac disorders0/2671/990/990/50
HypertensionVascular disorders0/2671/990/990/50
GastritisGastrointestinal disorders0/2671/990/990/50
Renal impairmentRenal and urinary disorders0/2670/991/990/50
Most frequent other events
Most frequent other events
EventSodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlacebo
ConstipationGastrointestinal disorders0/2671/999/990/50
OedemaGeneral disorders0/2671/998/990/50
Oedema peripheralGeneral disorders0/2674/997/990/50

Baseline characteristics

In RTP there were no subjects analyzed in Sodium Zirconium Cyclosilicate (ZS) 10g tid arm. In OLP, only ZS 10 g TID arm was present. All subjects in RTP took part in OLP.

Age, Continuous
Age, Continuous(Years)Sodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlaceboTotal
Mean67.8 ± 10.8066.7 ± 11.4068.0 ± 10.1869.4 ± 10.2667.7 ± 10.70
Sex: Female, Male
Sex: Female, Male(Participants)Sodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlaceboTotal
Female96363814184
Male171636136331
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlaceboTotal
Hispanic or Latino20114
Not Hispanic or Latino265999849511
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlaceboTotal
American Indian or Alaska Native00000
Asian227878643443
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White401213772
More than one race00000
Unknown or Not Reported00000
Country
Country(Participants)Sodium Zirconium Cyclosilicate (ZS) 10g TidSodium Zirconium Cyclosilicate (ZS) 5gSodium Zirconium Cyclosilicate (ZS) 10gPlaceboTotal
Japan68262713134
Korea121464523235
Russia401213772
Taiwan381514774
08

Study locations

45 sites
  • Research Site
    Chiba-shi, 260-8712, Japan
  • Research Site
    Hanyu-shi, 348-8505, Japan
  • Research Site
    Hitachinaka-shi, 312-0057, Japan
  • Research Site
    Ina-shi, 396-8555, Japan
  • Research Site
    Kanazawa-shi, 920-8650, Japan
  • Research Site
    Koga-shi, 306-0041, Japan
  • Research Site
    Matsudo-shi, 271-0077, Japan
  • Research Site
    Nagoya-shi, 457-8511, Japan
  • Research Site
    Nagoya-shi, 462-0802, Japan
  • Research Site
    Shimajiri-gun, 901-0493, Japan
  • Research Site
    Shizuoka-shi, 421-0117, Japan
  • Research Site
    Toride-shi, 302-0022, Japan
  • Research Site
    Toyohashi-shi, 441-8570, Japan
  • Research Site
    Yao-shi, 581-0011, Japan
  • Research Site
    Anyang-si, 14068, Korea, Republic of
  • Research Site
    Bucheon-si, 14647, Korea, Republic of
  • Research Site
    Bucheon-si, 14754, Korea, Republic of
  • Research Site
    Busan, 49241, Korea, Republic of
  • Research Site
    Cheongju-si, 28644, Korea, Republic of
  • Research Site
    Goyang-si, 10380, Korea, Republic of
  • Research Site
    Goyang-si, 10444, Korea, Republic of
  • Research Site
    Gwangju, 61469, Korea, Republic of
  • Research Site
    Hwaseong-si, 18450, Korea, Republic of
  • Research Site
    Incheon, 403-720, Korea, Republic of
  • Research Site
    Incheon, 405-760, Korea, Republic of
  • Research Site
    Seoul, 03080, Korea, Republic of
  • Research Site
    Seoul, 03312, Korea, Republic of
  • Research Site
    Seoul, 06591, Korea, Republic of
  • Research Site
    Seoul, 07061, Korea, Republic of
  • Research Site
    Seoul, 08308, Korea, Republic of
  • Research Site
    Suwon-si, Korea, Republic of
  • Research Site
    Uijeongbu-si, 11765, Korea, Republic of
  • Research Site
    Wonju-si, 26426, Korea, Republic of
  • Research Site
    Ekaterinburg, 620039, Russian Federation
  • Research Site
    Krasnoyarsk, 660062, Russian Federation
  • Research Site
    Moscow, 123423, Russian Federation
  • Research Site
    Saint Petersburg, 196601, Russian Federation
  • Research Site
    Saint-Petersburg, 194354, Russian Federation
  • Research Site
    Yaroslavl, 150062, Russian Federation
  • Research Site
    Hualien City, 970, Taiwan
  • Research Site
    New Taipei, 231, Taiwan
  • Research Site
    Taichung, 402, Taiwan
  • Research Site
    Taichung, 40705, Taiwan
  • Research Site
    Taipei, ROC 100, Taiwan
  • Research Site
    Taipei, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Feb 2018, 11 months.

Results were first posted in Aug 2020, 2 years 6 months after primary completion.

Of 18 phase 3 interventional studies under Hyperkalemia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2016
First posted
Aug 23, 2016
StartActual
Mar 3, 2017
Primary completionActual
Feb 14, 2018
CompletionActual
Feb 14, 2018
Results first posted
Aug 19, 2020
Last update
Aug 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02875834
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 23, 2016
Start date
Mar 3, 2017
Primary completion
Feb 14, 2018
Completion
Feb 14, 2018
Results posted
Aug 19, 2020
Last update
Aug 19, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium zirconium cyclosilicate

Start the discussion